Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Tanked Monday

By Eric Volkman - May 10, 2021 at 6:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's latest coronavirus vaccine news produced an unpleasant side effect.

What happened

Monday was eventful for vaccine specialist Novavax (NVAX 3.26%), with several updates overshadowing good financial news for the company. Novavax's shares, consequently, ended the day 8.8% lower.

So what

The most immediate event for Novavax was actually a positive one. In its first-quarter earnings release published Monday morning, the biotech revealed that it earned $447 million in revenue, miles ahead of the nearly $3.4 million in the same quarter of 2020. Net loss, though, deepened to almost $223 million ($3.05 per share) from the year-ago deficit of almost $26 million.

A child wincing from a vaccine shot.

Image source: Getty Images.

Both numbers beat the average analyst estimates of just under $234 million on the top line, and a per-share net loss of $3.60.

However, investors were likely more concerned with the company's news that the production of its NVX-CoV2373 coronavirus vaccine will ramp up more slowly than expected. Novavax now expects to reach its production goal of 150 million shots per month in the fourth quarter of this year, one quarter later than it previously aimed for. 

Compounding that, it added that it likely won't file for authorization from regulators in the U.S., the U.K., or the European Union until Q3.

Now what

Many Novavax investors are pinning their hopes on NVX-CoV2373 as for them the company is a play on the vaccine. Yet the pandemic is ebbing in many parts of the world, and competitors won authorization for their shots in those important jurisdictions first. Novavax certainly has promise, but that vaccine news wasn't exactly encouraging.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$43.68 (3.26%) $1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.